Sarah Cannon Research Institute
K36 Therapeutics Treats First Multiple Myeloma Patient in Phase I Trial of KTX-1001
The firm is evaluating its investigational MMSET inhibitor in patients with relapsed or refractory multiple myeloma harboring t(4;14) genetic translocations.
Mythic Therapeutics Treats First NSCLC Patient in Phase I Antibody-Drug Conjugate Trial
In the trial, Mythic will enroll patients based on their biomarker status, including cMET expression, MET amplification, and presence of MET exon 14 skipping mutations.
Harbinger Health, Sarah Cannon Research Institute to Study Blood-Based Early Cancer Detection Test
Harbinger has teamed up with SCRI's CRO to launch a 10,000-participant study to validate its multi-cancer early detection platform.
The researchers attributed the increase to the availability and ease of liquid biopsy testing and doctors using NGS to profile difficult-to-treat subtypes.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.